With valuations growing across the stock market and the biopharma sector, it's only natural for value-sensitive investors to ...

On a mission to collect a key Crohn’s disease approval and build out its inflammatory bowel disease (IBD) profile, Eli Lilly ...

Eli Lilly & Co plans to invest £279 million ($364 million) in a new initiative to support UK biotechs along with a study of ...

Eli Lilly’s Gateway Labs is going global, with the U.K. government announcing today that the nation will host the first ...

Chief Executive David Ricks told then-UK Health Secretary Victoria Atkins last December that the company’s new Alzheimer’s ...

On Friday, Eli Lilly And Co (LLY) stock saw a modest uptick, ending the day at $932.06 which represents a slight increase of $21.37 or 2.35% from the prior close of $910.69. The stock opened at ...

On Monday, Eli Lilly And Co (NYSE:LLY) announced data from a VIVID-1 Phase 3 study that evaluated the safety and efficacy of mirikizumab compared with a placebo and active control (Johnson & Johnson’s ...

Drugmaker Eli Lilly signed an agreement with the U.K. government to support early-stage life sciences businesses in the country. As part of the collaboration, which was announced Monday at the U.K.'s ...

The U.S. Food and Drug Administration (FDA) has agreed to reconsider its decision to remove tirzepatide, the active ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

However, the stock market largely attributes value to a company based on its ability to generate earnings in the future. Based on Lilly’s next twelve months forward P/E ratio, investors are paying ...

The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide from its ...